HSTC HST Global, Inc.
Pharmaceutical Preparations · OTC · SEC CIK 797564 · Fiscal year ends 12/31
Financial factors as of 2024-09-30 (2024Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY30.0%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-29.7%
ROA-15.8%
ROIC (approx.)-23.1%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets3.3%
Debt / equity0.00x
Current ratio0.25x
Interest coverage-28.94x
Cash quality & payout
Operating cash flow / net income0.38x
Accruals ratio-9.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2024Q32024-09-30 | 2024Q22024-06-30 | 2024Q12024-03-31 | 2023Q4*2023-12-31 | 2023Q32023-09-30 | 2023Q22023-06-30 | 2023Q12023-03-31 | 2022Q4*2022-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| SG&A expense | $13,400 | $16,556 | $2,688 | $5,474 | $4,368 | $2,990 | $8,075 | $4,588 |
| Operating income | -$13,400 | -$16,556 | -$32,688 | -$35,474 | -$34,368 | -$32,990 | -$38,075 | -$34,588 |
| Interest expense | $392 | $84 | $1,489 | $1,425 | $1,362 | $1,305 | $1,211 | $1,123 |
| Pretax income | -$13,792 | -$16,640 | -$34,177 | — | -$35,730 | -$34,295 | -$39,286 | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$13,792 | -$16,640 | -$34,177 | -$36,899 | -$35,730 | -$34,295 | -$39,286 | -$35,711 |
| EPS (basic) | 0.00 | 0.00 | -0.01 | — | -0.01 | -0.01 | -0.01 | — |
| EPS (diluted) | — | — | — | — | — | — | -0.01 | — |
| Weighted avg. shares (diluted) | — | — | — | — | — | — | 5.25M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $10,406 | $5,155 | $838 | $1,526 | $2,000 | $2,320 | $115 | $190 |
| Current assets | $10,406 | $5,155 | $838 | $1,526 | $2,000 | $2,320 | $115 | $190 |
| Intangibles | $1.27M | — | — | $0 | — | — | — | — |
| Total assets | $1.28M | $5,155 | $838 | $1,526 | $2,000 | $2,320 | $115 | $190 |
| Current liabilities | $42,076 | $23,034 | $627,082 | $593,593 | $557,168 | $521,758 | $485,258 | $446,047 |
| Total liabilities | $42,076 | $23,034 | $627,082 | $593,593 | $557,168 | $521,758 | $485,258 | $446,047 |
| Shareholders' equity | $1.24M | -$17,879 | -$626,244 | -$592,067 | -$555,168 | -$519,438 | -$485,143 | -$445,857 |
| Shares outstanding | — | — | — | 5.25M | — | — | — | 5.25M |
| Cash flow statement | ||||||||
| Operating cash flow | -$18,549 | $18,517 | -$32,688 | -$5,473 | -$4,369 | -$2,989 | -$38,075 | -$4,588 |
| Investing cash flow | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Financing cash flow | $23,800 | -$14,200 | $32,000 | $4,999 | $4,049 | $5,194 | $38,000 | $4,500 |
Free plan shows the latest 8 periods; Pro shows all 56 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.